Breast Cancer

Sarah Poland, MD, discussed the transition of breast cancer from an "immunologically cold" tumor to a target for checkpoint inhibitors, highlighting the pivotal role of the KEYNOTE-012 trial.

A novel agent in combination with olaparib has been granted fast track designation by the FDA for germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer.

Learn how ctDNA monitoring predicts breast cancer recurrence and detects ESR1/PIK3CA resistance, enabling earlier, personalized therapy switches.

Sarah Poland, MD, explored the evolution of immunotherapy in breast cancer, including in triple-negative disease and HR+ and HER2+ subtypes.

J. Isabelle Choi, MD, shared her specific fractionation preferences and prophylactic strategies to combat adverse effects associated with radiation.

A Prescription Drug User Fee Act date of December 18, 2026, has been set for giredestrant plus everolimus in ER+, HER2–, ESR1-mutated breast cancer.

Sunil W. Dutta, MD, discussed why clinical follow-up remains an essential soft skill for radiation oncologists in an increasingly automated field.

J. Isabelle Choi, MD, discussed proton and photon therapy for locoregional recurrences, emphasizing advanced IMRT/VMAT techniques and CTV delineation.

Since 2003, breast cancer has been one of the black box warnings associated with hormone replacement therapy for women experiencing menopause.

Sunil W. Dutta, MD, discussed hypofractionation in breast reconstruction and why clinical follow up remains a key "soft skill" in an AI-driven field.

Sunil Dutta, MD, discusses integrating FAST-Forward and PRIME II trial data to personalize breast cancer treatment and sequencing radiation with ADCs.

In this review, we highlight pivotal trials that have informed current practice and ongoing trials that may inform the therapeutic landscape in the coming years.

Fumiko Chino, MD, FASCO, discussed the psychological "free fall" patients may experience after completion of radiation therapy for breast cancer.

Surgical updates for invasive breast cancer from the NCCN Breast Cancer meeting revealed insights on neoadjuvant endocrine therapy and SLNB omission.

Parul Barry, MD, discussed the evolving role of ADCs and targeted therapies in breast cancer, highlighting strategies for sequencing them with radiation.

Because there are so many options available for treating DCIS, the chosen method is often based on the patient's preferences, said Jean L. Wright, MD, FASTRO.

Certain strategies are needed to improve clinical trial diversity, focusing on building patient trust, increasing workforce representation, and reducing logistical burdens.

Parul Barry, MD, discusses advances such as ultrahypofractionated radiation and the growing role of AI in streamlining workflows for breast cancer care.

J. Isabelle Choi, MD, outlined evidence-based strategies for radiation dose escalation in locoregionally advanced breast cancer.

Ifeoma Dikeocha, PhD, discussed how metabolic restriction and fasting-mimicking diets can help optimize chemotherapy outcomes in breast cancer.

A PDUFA date in the second quarter of 2026 has been set for Dato-DXd in patients with unresectable or metastatic TNBC.

In the PATINA trial, adding palbociclib to maintenance therapy significantly improved progression-free survival in patients with HR+, HER2+ breast cancer.

Results of 9 patients with metastatic breast cancer dosed with Bria-IMT have shown sustained survival.

The FDA held a Type B meeting regarding the use of d3-T, a form of testosterone, and the risk of developing breast cancer in women.

Paxalisib combined with pembrolizumab and chemotherapy showed preliminary activity in patients with metastatic triple-negative breast cancer.